Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget
- Monday, April 26, 2021, 7:04
- Finance
- Add a comment
DALLAS, April 26, 2021 /PRNewswire/ — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform oncology drug discovery and development, announced a manuscript describing the efficacy…
About the Author
adminasapcorp has written 41555 stories on this site.